Latest Industry Insights

In this interview, Technology Networks spoke to Heiko Neuweger, director of Bioinformatics Life Science Mass Spectrometry Software R&D at Bruker, to learn about the importance of target compound annotation and identification, the advantages of integrating collision cross section (CCS) information into workflows and the benefits of CCS-Predict Pro.

Technology Networks spoke to Dr. Markus Gershater to learn more about Synthace's Lab automation & experimentation in life science R&D 2023-2024 report, its findings and their significance.

Technology Networks spoke to Dr. Jasper Van Hoorick to learn more about the future of bioprinting, the benefits of animal-free bioinks and the development of human tissue-based bioinks.

With growing sustainability demands, companies are looking for ways to demonstrate their green credentials. We spoke to Dr. Michael Frank to find out what ACT accreditation means for a company and why he thinks schemes like this are so important.

Scientists around the world are increasingly aware of the environmental footprint of their laboratories, and many are adjusting the way they work day-to-day to offset this impact. In this Industry Insights interview, Agilent's Dr. Michael Frank discusses the safety and efficiency considerations that are fundamentally linked to sustainability and considers why more labs aren’t utilizing consulting services to help them achieve their sustainability goals.

How can the industry as a whole address sustainability issues? What are the key needs and goals of pharma and biopharma laboratories when it comes to sustainability?

BetterLife Pharma’s lead candidate is a non-hallucinogenic derivative of LSD that mimics the projected therapeutic properties of LSD. To learn more, we spoke with BetterLife Pharma’s chief operating officer, Dr. Hooshmand Sheshbaradaran, and head of preclinical research, Dr. Abdi Ghaffari.

HPLC system manufacturers have been striving to improve usability, accessibility and help users improve their experimental outcomes. And what better way to do that than to involve the users themselves in that development process.

To learn more about the progress and development of non-hallucinogenic psychedelic therapies for conditions such as depression, Technology Networks spoke with the head of research and development at Delix Therapeutics, Dr. Eliseo Salinas.

Explore the importance of location-specific expertise in global research collaborations and how to overcome challenges faced by in-house R&D teams when engaging with global partners.